Cellectis presented preclinical data for .HEAL-101, a gene editing therapy targeting APOC3 to treat severe hypertriglyceridemia. The therapy achieved up to 70% APOC3 gene editing in mice and reduced triglyceride levels by 76% after a single dose. This liver-targeted treatment showed no off-target effects and supports advancing to a Phase 1 clinical trial in China expected in late 2027. These results highlight .HEAL-101's potential as a one-time treatment for patients with high triglycerides.
Cellectis' gene editing therapy .HEAL-101 is noted here alongside Pluang's Health sector market data as of Oct 27, 2026 13:11 WIB. Of 150 priced Health-sector US stocks tradable on Pluang, 79 rose and 67 fell today. Notable movers include AMWL at USD 14.20 with a 1-day change of +4.64%, IBRX at USD 7.86 with -4.38%, and CRL at USD 360.00 with +4.24% and 100% buy order activity, typical hold time 34 days.
Vertex, Inc. has introduced Vertex Sōl™, a connected AI-powered solution that integrates tax and compliance processes across the entire tax lifecycle. This platform links workflows, evidence, and expert-driven AI to provide full transparency and cont...
Roche has received the CE Mark for its new cobas smart e immunoanalyser, a compact device designed to deliver central-lab quality testing in smaller healthcare settings. With over 100 planned assays and rapid reaction times under 18 minutes for most ...
Ethereum developers patched a critical bug in the upcoming Glamsterdam upgrade that could have allowed an operator to withdraw ETH meant for new validators by exploiting shared public keys between builders and validators. This flaw risked staking dep...
The share of Bitcoin held at a profit by short-term holders has fallen from nearly 100% in late September to about 70%, signaling reduced selling pressure. This decline follows a correction after Bitcoin's attempt to recover above $85,000, with reali...
NEAR Protocol's native token has been listed for trading, deposits, and withdrawals on the Gemini exchange, providing U.S. investors with another access point. Despite this, NEAR's price remains under pressure, trading around $4.42 and down about 12%...
